EGFR and non-small cell lung carcinoma: In the phase 3 study (NCT04487080), amivantamab-lazertinib was more effective than osimertinib in patients with EGFR-negative advanced NSCLC, with significantly longer PFS (23.7 months vs. 16.6 months; p < 0.001) and median DOR (25.8 months vs. 16.8 months).